image
Healthcare - Medical - Devices - NASDAQ - US
$ 1.69
-4.52 %
$ 28.1 M
Market Cap
-2.68
P/E
1. INTRINSIC VALUE

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders.[ Read More ]

The intrinsic value of one IRIX stock under the base case scenario is HIDDEN Compared to the current market price of 1.69 USD, IRIDEX Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart IRIX

image
FINANCIALS
51.9 M REVENUE
-8.96%
-10 M OPERATING INCOME
-32.68%
-9.57 M NET INCOME
-26.81%
-6.74 M OPERATING CASH FLOW
29.14%
-109 K INVESTING CASH FLOW
61.89%
-5 K FINANCING CASH FLOW
93.15%
11.6 M REVENUE
-8.31%
-1.87 M OPERATING INCOME
29.11%
-1.93 M NET INCOME
27.85%
-3.07 M OPERATING CASH FLOW
-131.75%
-1 K INVESTING CASH FLOW
0.00%
2.82 M FINANCING CASH FLOW
0.00%
Balance Sheet Decomposition IRIDEX Corporation
image
Current Assets 27.4 M
Cash & Short-Term Investments 7.03 M
Receivables 9.65 M
Other Current Assets 10.8 M
Non-Current Assets 6.99 M
Long-Term Investments 0
PP&E 2.98 M
Other Non-Current Assets 4 M
Current Liabilities 13 M
Accounts Payable 4.5 M
Short-Term Debt 1.99 M
Other Current Liabilities 6.48 M
Non-Current Liabilities 11.9 M
Long-Term Debt 3.5 M
Other Non-Current Liabilities 8.44 M
EFFICIENCY
Earnings Waterfall IRIDEX Corporation
image
Revenue 51.9 M
Cost Of Revenue 30.1 M
Gross Profit 21.8 M
Operating Expenses 31.8 M
Operating Income -10 M
Other Expenses -437 K
Net Income -9.57 M
RATIOS
42.04% GROSS MARGIN
42.04%
-19.29% OPERATING MARGIN
-19.29%
-18.45% NET MARGIN
-18.45%
-100.50% ROE
-100.50%
-27.79% ROA
-27.79%
-82.34% ROIC
-82.34%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis IRIDEX Corporation
image
Net Income -9.57 M
Depreciation & Amortization 2.03 M
Capital Expenditures -109 K
Stock-Based Compensation 1.65 M
Change in Working Capital -857 K
Others -2.5 M
Free Cash Flow -6.85 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets IRIDEX Corporation
image
IRIX has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership IRIDEX Corporation
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
2 years ago
May 20, 2022
Bought 6.2 K USD
Devi Nandini
director:
+ 2000
3.0999 USD
2 years ago
Mar 16, 2022
Bought 8.4 K USD
Devi Nandini
director:
+ 2000
4.2 USD
2 years ago
Dec 02, 2021
Bought 10 K USD
Grove Robert Earle
Director
+ 1644
6.082 USD
3 years ago
Nov 16, 2021
Bought 7.73 K USD
Devi Nandini
Director
+ 1000
7.7298 USD
4 years ago
May 15, 2020
Bought 25.4 K USD
Grove Robert Earle
Director
+ 15125
1.6824 USD
5 years ago
Nov 18, 2019
Bought 2.03 K USD
Grove Robert Earle
Director
+ 1000
2.0282 USD
5 years ago
Nov 18, 2019
Bought 20.4 K USD
Grove Robert Earle
Director
+ 10000
2.0377 USD
5 years ago
Nov 18, 2019
Bought 7.34 K USD
Grove Robert Earle
Director
+ 3600
2.04 USD
5 years ago
Nov 15, 2019
Bought 20.2 K USD
Grove Robert Earle
Director
+ 10000
2.0187 USD
5 years ago
Nov 14, 2019
Bought 20.2 K USD
Shuda Scott
Director
+ 10000
2.02 USD
5 years ago
Nov 13, 2019
Bought 10 K USD
Shuda Scott
Director
+ 5000
2.01 USD
5 years ago
Dec 13, 2018
Bought 3.71 K USD
Grove Robert Earle
Director
+ 863
4.3 USD
5 years ago
Dec 12, 2018
Bought 43.4 K USD
MOORE WILLIAM M
Chairman and CEO
+ 10000
4.3443 USD
5 years ago
Dec 12, 2018
Bought 15.9 K USD
Grove Robert Earle
Director
+ 3684
4.3169 USD
5 years ago
Dec 11, 2018
Bought 19.5 K USD
Grove Robert Earle
Director
+ 4673
4.182 USD
5 years ago
Dec 10, 2018
Bought 10.4 K USD
Grove Robert Earle
Director
+ 2500
4.1728 USD
5 years ago
Nov 27, 2018
Bought 47.1 K USD
MOORE WILLIAM M
Chairman and CEO
+ 10000
4.7144 USD
6 years ago
Sep 18, 2018
Bought 420 K USD
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE
+ 70000
6 USD
6 years ago
Sep 14, 2018
Bought 65.6 K USD
MOORE WILLIAM M
Chairman and CEO
+ 10000
6.56 USD
7 years ago
Aug 25, 2017
Bought 2.05 K USD
Acuta Capital Fund, LP
10 percent owner
+ 236
8.6658 USD
7 years ago
Aug 22, 2017
Bought 4.21 K USD
Acuta Capital Fund, LP
10 percent owner
+ 500
8.4245 USD
7 years ago
Aug 16, 2017
Bought 19 K USD
Acuta Capital Fund, LP
10 percent owner
+ 2260
8.4034 USD
7 years ago
Aug 15, 2017
Bought 4.74 K USD
Acuta Capital Fund, LP
10 percent owner
+ 555
8.5459 USD
7 years ago
Aug 11, 2017
Bought 45.5 K USD
Acuta Capital Fund, LP
10 percent owner
+ 5365
8.4762 USD
7 years ago
Aug 10, 2017
Bought 24.1 K USD
Acuta Capital Fund, LP
10 percent owner
+ 2852
8.4607 USD
7 years ago
Aug 09, 2017
Bought 83.6 K USD
Acuta Capital Fund, LP
10 percent owner
+ 9730
8.5953 USD
7 years ago
Aug 08, 2017
Bought 108 K USD
Acuta Capital Fund, LP
10 percent owner
+ 13185
8.1814 USD
7 years ago
Aug 07, 2017
Bought 4.94 K USD
Acuta Capital Fund, LP
10 percent owner
+ 600
8.2282 USD
7 years ago
Aug 04, 2017
Bought 134 K USD
Acuta Capital Fund, LP
10 percent owner
+ 16402
8.1788 USD
7 years ago
Aug 03, 2017
Bought 17.7 K USD
Acuta Capital Fund, LP
10 percent owner
+ 2040
8.6671 USD
7 years ago
Aug 02, 2017
Bought 41 K USD
Acuta Capital Fund, LP
10 percent owner
+ 4685
8.7567 USD
7 years ago
Aug 01, 2017
Bought 73.6 K USD
Acuta Capital Fund, LP
10 percent owner
+ 8055
9.1373 USD
7 years ago
Jul 31, 2017
Bought 48.5 K USD
Acuta Capital Fund, LP
10 percent owner
+ 5137
9.4453 USD
7 years ago
Jul 28, 2017
Bought 82 K USD
Acuta Capital Fund, LP
10 percent owner
+ 8633
9.5023 USD
7 years ago
Jul 27, 2017
Bought 70.5 K USD
Acuta Capital Fund, LP
10 percent owner
+ 7442
9.4684 USD
7 years ago
Jul 26, 2017
Bought 42.5 K USD
Acuta Capital Fund, LP
10 percent owner
+ 4415
9.621 USD
7 years ago
Jul 25, 2017
Bought 6.45 K USD
Acuta Capital Fund, LP
10 percent owner
+ 670
9.62 USD
7 years ago
Jul 24, 2017
Bought 27.7 K USD
Acuta Capital Fund, LP
10 percent owner
+ 2895
9.5737 USD
7 years ago
Jul 21, 2017
Bought 67 K USD
Acuta Capital Fund, LP
10 percent owner
+ 7020
9.5374 USD
7 years ago
Jul 20, 2017
Bought 29.8 K USD
Acuta Capital Fund, LP
10 percent owner
+ 3115
9.557 USD
7 years ago
Jul 19, 2017
Bought 39 K USD
Acuta Capital Fund, LP
10 percent owner
+ 4141
9.4172 USD
7 years ago
Jul 18, 2017
Bought 34.7 K USD
Acuta Capital Fund, LP
10 percent owner
+ 3695
9.3902 USD
7 years ago
Jul 17, 2017
Bought 18.9 K USD
Acuta Capital Fund, LP
10 percent owner
+ 2017
9.3879 USD
7 years ago
Jul 14, 2017
Bought 29 K USD
Acuta Capital Fund, LP
10 percent owner
+ 3071
9.4336 USD
7 years ago
Jul 13, 2017
Bought 46.7 K USD
Acuta Capital Fund, LP
10 percent owner
+ 5017
9.3097 USD
7 years ago
Jul 12, 2017
Bought 91.2 K USD
Acuta Capital Fund, LP
10 percent owner
+ 9742
9.361 USD
7 years ago
Jul 11, 2017
Bought 148 K USD
Acuta Capital Fund, LP
10 percent owner
+ 15545
9.5294 USD
7 years ago
Jul 10, 2017
Bought 66.6 K USD
Acuta Capital Fund, LP
10 percent owner
+ 6933
9.6064 USD
7 years ago
Jul 07, 2017
Bought 79.1 K USD
Acuta Capital Fund, LP
10 percent owner
+ 8217
9.6228 USD
7 years ago
Jul 06, 2017
Bought 168 K USD
Acuta Capital Fund, LP
10 percent owner
+ 17600
9.5318 USD
7 years ago
Jul 05, 2017
Bought 30.3 K USD
Acuta Capital Fund, LP
10 percent owner
+ 3183
9.5298 USD
7 years ago
Jul 03, 2017
Bought 26.9 K USD
Acuta Capital Fund, LP
10 percent owner
+ 2756
9.7493 USD
6 years ago
Mar 13, 2018
Sell 16.4 K USD
Dizon Romeo R
- 2806
5.8602 USD
6 years ago
Dec 12, 2017
Bought 39.2 K USD
MOORE WILLIAM M
Chairman and CEO
+ 5000
7.84 USD
7 years ago
Sep 15, 2017
Bought 17 K USD
MOORE WILLIAM M
Chairman and CEO
+ 1800
9.42 USD
7 years ago
Mar 15, 2017
Sell 37 K USD
Dizon Romeo R
- 2811
13.1583 USD
8 years ago
Nov 16, 2016
Sell 2 K USD
Dizon Romeo R
- 125
16.04 USD
8 years ago
Sep 12, 2016
Sell 930 USD
Dizon Romeo R
- 62
15 USD
8 years ago
Sep 02, 2016
Sell 37 K USD
NAUMANN-ETIENNE RUEDIGER
Director
- 2513
14.73 USD
8 years ago
Sep 07, 2016
Sell 103 K USD
NAUMANN-ETIENNE RUEDIGER
Director
- 7000
14.7618 USD
8 years ago
Aug 23, 2016
Sell 12.7 K USD
Dizon Romeo R
- 875
14.5234 USD
8 years ago
Aug 19, 2016
Sell 14.4 K USD
Dizon Romeo R
- 1063
13.5031 USD
8 years ago
Aug 19, 2016
Sell 14.7 K USD
Dizon Romeo R
- 1084
13.518 USD
8 years ago
Aug 19, 2016
Sell 11.8 K USD
Dizon Romeo R
- 875
13.504 USD
8 years ago
Aug 19, 2016
Sell 25.3 K USD
Dizon Romeo R
- 1875
13.5005 USD
8 years ago
Aug 19, 2016
Sell 8.26 K USD
Dizon Romeo R
- 608
13.59 USD
8 years ago
Aug 19, 2016
Sell 4.54 K USD
Dizon Romeo R
- 335
13.556 USD
8 years ago
Aug 19, 2016
Sell 2.72 K USD
Dizon Romeo R
- 200
13.6 USD
8 years ago
Aug 18, 2016
Sell 22.5 K USD
Dizon Romeo R
- 1667
13.5 USD
8 years ago
Aug 16, 2016
Sell 11.5 K USD
Dizon Romeo R
- 839
13.7 USD
8 years ago
Aug 16, 2016
Sell 34.1 K USD
Marcellino George R
Director
- 2513
13.5702 USD
8 years ago
Jun 06, 2016
Sell 8.45 K USD
Steckel Ronald
VP, Operations
- 625
13.5168 USD
8 years ago
May 17, 2016
Sell 16 K USD
Steckel Ronald
VP, Operations
- 1250
12.8187 USD
8 years ago
May 17, 2016
Sell 16 K USD
Steckel Ronald
VP, Operations
- 1250
12.7944 USD
8 years ago
Mar 08, 2016
Sell 39.2 K USD
Steckel Ronald
VP, Operations
- 3750
10.4481 USD
8 years ago
Mar 08, 2016
Sell 20.9 K USD
Steckel Ronald
VP, Operations
- 2000
10.4625 USD
9 years ago
Nov 19, 2015
Bought 98.3 K USD
MOORE WILLIAM M
Chairman and CEO
+ 10000
9.8326 USD
9 years ago
Sep 25, 2015
Bought 35.1 K USD
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE
10 percent owner
+ 5000
7.02 USD
9 years ago
Sep 24, 2015
Bought 94.3 K USD
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE
10 percent owner
+ 13542
6.96 USD
9 years ago
Sep 23, 2015
Bought 238 K USD
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE
10 percent owner
+ 33500
7.09 USD
9 years ago
Sep 10, 2015
Bought 57.6 K USD
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE
10 percent owner
+ 8259
6.97 USD
9 years ago
Sep 09, 2015
Bought 24.9 K USD
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE
10 percent owner
+ 3607
6.89 USD
9 years ago
Sep 04, 2015
Bought 35.5 K USD
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE
10 percent owner
+ 5200
6.83 USD
9 years ago
Sep 03, 2015
Bought 18.5 K USD
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE
10 percent owner
+ 2704
6.83 USD
9 years ago
Sep 02, 2015
Bought 16.2 K USD
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE
10 percent owner
+ 2400
6.75 USD
9 years ago
Sep 02, 2015
Sell 12.8 K USD
Steckel Ronald
VP, Operations
- 1875
6.8 USD
9 years ago
Aug 19, 2015
Sell 17 K USD
Mackaness James H
CFO and COO
- 2373
7.15 USD
9 years ago
Aug 21, 2015
Bought 63.6 K USD
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE
10 percent owner
+ 8851
7.18 USD
9 years ago
Aug 20, 2015
Bought 73.7 K USD
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE
10 percent owner
+ 10300
7.16 USD
9 years ago
Aug 19, 2015
Bought 10.6 K USD
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE
10 percent owner
+ 1500
7.06 USD
9 years ago
Aug 19, 2015
Sell 4.92 K USD
Steckel Ronald
VP, Operations
- 684
7.2 USD
9 years ago
Aug 19, 2015
Sell 475 USD
Steckel Ronald
VP, Operations
- 67
7.0825 USD
9 years ago
Aug 19, 2015
Sell 7.1 K USD
Steckel Ronald
VP, Operations
- 1000
7.1 USD
9 years ago
Aug 18, 2015
Sell 908 USD
Mackaness James H
CFO and COO
- 127
7.15 USD
9 years ago
Aug 18, 2015
Sell 17.8 K USD
Mackaness James H
CFO and COO
- 2500
7.1 USD
9 years ago
Aug 17, 2015
Sell 15.8 K USD
Mackaness James H
CFO and COO
- 2235
7.05 USD
9 years ago
Aug 14, 2015
Sell 19.5 K USD
Mackaness James H
CFO and COO
- 2765
7.05 USD
9 years ago
Aug 13, 2015
Sell 34.8 K USD
Mackaness James H
CFO and COO
- 5000
6.95 USD
9 years ago
Aug 14, 2015
Sell 19.5 K USD
Mackaness James H
CFO and COO
- 2765
7.05 USD
9 years ago
Aug 13, 2015
Sell 34.8 K USD
Mackaness James H
CFO and COO
- 5000
6.95 USD
9 years ago
Aug 13, 2015
Sell 2.8 K USD
Steckel Ronald
VP, Operations
- 400
7 USD
9 years ago
Aug 14, 2015
Sell 7 K USD
Steckel Ronald
VP, Operations
- 1000
7 USD
9 years ago
Aug 07, 2015
Bought 45.8 K USD
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE
10 percent owner
+ 6324
7.24 USD
9 years ago
Aug 06, 2015
Bought 264 K USD
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE
10 percent owner
+ 40210
6.56 USD
9 years ago
Aug 05, 2015
Bought 298 K USD
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE
10 percent owner
+ 45000
6.63 USD
9 years ago
Jul 24, 2015
Bought 112 K USD
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE
10 percent owner
+ 15984
6.98 USD
9 years ago
Jul 23, 2015
Bought 172 K USD
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE
10 percent owner
+ 24419
7.03 USD
9 years ago
Jun 17, 2015
Sell 9.13 K USD
Steckel Ronald
VP, Operations
- 1041
8.7674 USD
9 years ago
May 20, 2015
Sell 19.6 K USD
Mackaness James H
CFO and COO
- 2000
9.8045 USD
9 years ago
May 18, 2015
Sell 9.72 K USD
Steckel Ronald
VP, Operations
- 1042
9.3264 USD
9 years ago
Apr 20, 2015
Sell 14.2 K USD
Steckel Ronald
VP, Operations
- 1447
9.7897 USD
9 years ago
Apr 17, 2015
Sell 10.3 K USD
Steckel Ronald
VP, Operations
- 1042
9.8617 USD
9 years ago
Mar 17, 2015
Sell 13.9 K USD
Steckel Ronald
VP, Operations
- 1375
10.079 USD
9 years ago
Mar 17, 2015
Sell 101 K USD
Steckel Ronald
VP, Operations
- 9983
10.079 USD
9 years ago
Mar 10, 2015
Sell 12.5 K USD
Steckel Ronald
VP, Operations
- 1250
10.0342 USD
9 years ago
Feb 17, 2015
Sell 10 K USD
Steckel Ronald
VP, Operations
- 1025
9.7936 USD
9 years ago
Jan 20, 2015
Sell 9.25 K USD
Steckel Ronald
VP, Operations
- 1025
9.0291 USD
9 years ago
Dec 17, 2014
Sell 8.74 K USD
Steckel Ronald
VP, Operations
- 1025
8.5221 USD
10 years ago
Nov 17, 2014
Sell 8.49 K USD
Steckel Ronald
VP, Operations
- 1025
8.2833 USD
10 years ago
Oct 12, 2014
Bought 140 K USD
BlueLine Catalyst Fund IX, L.P.
director, 10 percent owner:
+ 17237
8.11 USD
10 years ago
Oct 10, 2014
Bought 103 K USD
BlueLine Catalyst Fund IX, L.P.
director, 10 percent owner:
+ 12798
8.02 USD
10 years ago
Nov 07, 2014
Sell 16.4 K USD
Steckel Ronald
VP, Operations
- 2050
8 USD
10 years ago
Oct 07, 2014
Bought 32.4 K USD
BlueLine Catalyst Fund IX, L.P.
director, 10 percent owner:
+ 4050
8 USD
10 years ago
Oct 06, 2014
Bought 21.3 K USD
BlueLine Catalyst Fund IX, L.P.
director, 10 percent owner:
+ 2732
7.78 USD
10 years ago
Nov 06, 2014
Bought 37.4 K USD
MOORE WILLIAM M
Director
+ 4800
7.79 USD
10 years ago
Nov 05, 2014
Bought 1.55 K USD
MOORE WILLIAM M
Director
+ 200
7.75 USD
10 years ago
Sep 05, 2014
Bought 63.4 K USD
BlueLine Catalyst Fund IX, L.P.
director, 10 percent owner:
+ 7932
7.99 USD
10 years ago
Sep 04, 2014
Bought 1.6 K USD
BlueLine Catalyst Fund IX, L.P.
director, 10 percent owner:
+ 200
7.99 USD
10 years ago
Sep 03, 2014
Bought 2.39 K USD
BlueLine Catalyst Fund IX, L.P.
director, 10 percent owner:
+ 300
7.98 USD
10 years ago
Sep 05, 2014
Bought 63.4 K USD
BlueLine Catalyst Fund IX, L.P.
director, 10 percent owner:
+ 7932
7.99 USD
10 years ago
Sep 04, 2014
Bought 1.6 K USD
BlueLine Catalyst Fund IX, L.P.
director, 10 percent owner:
+ 200
7.99 USD
10 years ago
Sep 03, 2014
Bought 2.39 K USD
BlueLine Catalyst Fund IX, L.P.
director, 10 percent owner:
+ 300
7.98 USD
10 years ago
Aug 29, 2014
Bought 26.9 K USD
BlueLine Catalyst Fund IX, L.P.
director, 10 percent owner:
+ 3392
7.93 USD
10 years ago
Aug 28, 2014
Bought 3.78 K USD
BlueLine Catalyst Fund IX, L.P.
director, 10 percent owner:
+ 480
7.87 USD
10 years ago
Aug 27, 2014
Bought 3.17 K USD
BlueLine Catalyst Fund IX, L.P.
director, 10 percent owner:
+ 400
7.92 USD
10 years ago
Aug 29, 2014
Bought 26.9 K USD
BlueLine Catalyst Fund IX, L.P.
director, 10 percent owner:
+ 3392
7.93 USD
10 years ago
Aug 28, 2014
Bought 3.78 K USD
BlueLine Catalyst Fund IX, L.P.
director, 10 percent owner:
+ 480
7.87 USD
10 years ago
Aug 27, 2014
Bought 3.17 K USD
BlueLine Catalyst Fund IX, L.P.
director, 10 percent owner:
+ 400
7.92 USD
10 years ago
Aug 22, 2014
Sell 4.82 K USD
HAWKINS JAMES B
Director
- 600
8.03 USD
10 years ago
Aug 18, 2014
Sell 8.2 K USD
Steckel Ronald
VP, Operations
- 1025
8 USD
10 years ago
Aug 15, 2014
Sell 15.3 K USD
HAWKINS JAMES B
Director
- 1900
8.0703 USD
10 years ago
Aug 13, 2014
Sell 79.3 K USD
HAWKINS JAMES B
Director
- 9786
8.1081 USD
10 years ago
Aug 14, 2014
Sell 21.9 K USD
HAWKINS JAMES B
Director
- 2714
8.0812 USD
10 years ago
Aug 11, 2014
Sell 23.3 K USD
GARRETTSON GARRETT A
Director
- 2810
8.3 USD
10 years ago
Aug 05, 2014
Sell 2.11 K USD
Steckel Ronald
VP, Operations
- 264
8 USD
10 years ago
Jul 31, 2014
Sell 6.09 K USD
Steckel Ronald
VP, Operations
- 761
8 USD
10 years ago
Jul 21, 2014
Sell 7.62 K USD
Mackaness James H
CFO and COO
- 1000
7.615 USD
10 years ago
Jun 23, 2014
Sell 8.23 K USD
Mackaness James H
CFO and COO
- 1000
8.2305 USD
10 years ago
Jun 23, 2014
Sell 8.26 K USD
Mackaness James H
CFO and COO
- 1000
8.2579 USD
10 years ago
Jun 17, 2014
Sell 8.41 K USD
Steckel Ronald
VP, Operations
- 1025
8.2032 USD
10 years ago
Jun 06, 2014
Sell 42 K USD
FITCH SANFORD
Director
- 5000
8.39 USD
10 years ago
Jun 06, 2014
Bought 61.5 K USD
BlueLine Catalyst Fund IX, L.P.
director, 10 percent owner:
+ 7390
8.32 USD
10 years ago
Jun 03, 2014
Bought 42.4 K USD
MOORE WILLIAM M
Chairman and CEO
+ 5000
8.48 USD
10 years ago
May 21, 2014
Sell 8.8 K USD
Mackaness James H
CFO and COO
- 1000
8.7995 USD
10 years ago
May 21, 2014
Sell 8.75 K USD
Mackaness James H
CFO and COO
- 1000
8.7455 USD
10 years ago
May 21, 2014
Sell 8.64 K USD
Mackaness James H
CFO and COO
- 1000
8.6435 USD
10 years ago
May 19, 2014
Sell 9.04 K USD
Steckel Ronald
VP, Operations
- 1025
8.8152 USD
10 years ago
May 09, 2014
Bought 42 K USD
MOORE WILLIAM M
Chairman and CEO
+ 5000
8.4 USD
10 years ago
Apr 21, 2014
Sell 8.65 K USD
Mackaness James H
CFO and COO
- 1000
8.646 USD
10 years ago
Apr 21, 2014
Sell 17.3 K USD
Mackaness James H
CFO and COO
- 2000
8.655 USD
10 years ago
Apr 22, 2014
Sell 9 K USD
Mackaness James H
CFO and COO
- 1000
9 USD
10 years ago
Apr 17, 2014
Sell 9.1 K USD
Steckel Ronald
VP, Operations
- 1025
8.88 USD
10 years ago
Mar 21, 2014
Sell 9.03 K USD
Mackaness James H
CFO and COO
- 1000
9.0283 USD
10 years ago
Mar 21, 2014
Sell 9.04 K USD
Mackaness James H
CFO and COO
- 1000
9.0367 USD
10 years ago
Mar 21, 2014
Sell 9.04 K USD
Mackaness James H
CFO and COO
- 1000
9.0378 USD
10 years ago
Mar 21, 2014
Sell 9.04 K USD
Mackaness James H
CFO and COO
- 1000
9.0365 USD
10 years ago
Mar 17, 2014
Sell 9.3 K USD
Steckel Ronald
VP, Operations
- 1025
9.07 USD
10 years ago
Feb 18, 2014
Sell 8.82 K USD
Steckel Ronald
VP, Operations
- 1025
8.6 USD
10 years ago
Mar 04, 2014
Sell 46.1 K USD
GARRETTSON GARRETT A
Director
- 4993
9.2238 USD
10 years ago
Feb 18, 2014
Sell 8.82 K USD
Steckel Ronald
VP, Operations
- 1025
8.6 USD
10 years ago
Feb 18, 2014
Sell 5.38 K USD
Steckel Ronald
VP, Operations
- 625
8.6 USD
10 years ago
Jan 17, 2014
Sell 10.7 K USD
Steckel Ronald
VP, Operations
- 1025
10.4201 USD
10 years ago
Jan 17, 2014
Sell 6.51 K USD
Steckel Ronald
VP, Operations
- 625
10.4201 USD
10 years ago
Dec 17, 2013
Sell 8.77 K USD
Steckel Ronald
VP, Operations
- 1025
8.56 USD
10 years ago
Dec 17, 2013
Sell 5.35 K USD
Steckel Ronald
VP, Operations
- 625
8.56 USD
10 years ago
Dec 02, 2013
Sell 105 K USD
Mackaness James H
CFO and COO
- 10000
10.5218 USD
11 years ago
Nov 18, 2013
Sell 8.91 K USD
Steckel Ronald
VP, Operations
- 1025
8.69 USD
11 years ago
Nov 18, 2013
Sell 5.43 K USD
Steckel Ronald
VP, Operations
- 625
8.69 USD
11 years ago
Nov 06, 2013
Sell 83.5 K USD
Mackaness James H
CFO and COO
- 10000
8.3496 USD
11 years ago
Nov 04, 2013
Sell 80.6 K USD
Steckel Ronald
VP, Operations
- 10075
8 USD
11 years ago
Nov 04, 2013
Sell 39 K USD
Steckel Ronald
VP, Operations
- 4875
8 USD
11 years ago
Sep 06, 2013
Bought 15.5 K USD
NAUMANN-ETIENNE RUEDIGER
Director
+ 2584
5.99 USD
11 years ago
Sep 05, 2013
Bought 6 K USD
NAUMANN-ETIENNE RUEDIGER
Director
+ 1001
5.99 USD
11 years ago
Sep 04, 2013
Bought 88.5 USD
NAUMANN-ETIENNE RUEDIGER
Director
+ 15
5.9 USD
11 years ago
Aug 09, 2013
Bought 57.6 K USD
MOORE WILLIAM M
Chairman and CEO
+ 9800
5.882 USD
11 years ago
Aug 08, 2013
Bought 1.16 K USD
MOORE WILLIAM M
Chairman and CEO
+ 200
5.8 USD
7. News
Iridex to Report Third Quarter 2024 Financial Results on November 12, 2024 MOUNTAIN VIEW, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the third quarter 2024 and provide a business update after the close of trading on Tuesday, November 12, 2024. globenewswire.com - 1 week ago
Iridex Appoints Patrick Mercer as Chief Executive Officer MOUNTAIN VIEW, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the appointment of Patrick Mercer as the Company's Chief Executive Officer and President effective October 1, 2024. Previously Mr. Mercer served as the Company's Chief Operating Officer and President. David Bruce, the Company's prior Chief Executive Officer, is transitioning from the Company. Coincident to Mr. Mercer's appointment, Scott Shuda was appointed Executive Chairman of the Company's board of directors. Mr. Shuda had previously served as Chairman. globenewswire.com - 1 month ago
Iridex Frustrates, But Expect A Transaction By Year-End IRIDEX has faced delays in selling its assets as part of a strategic review initiated a year ago, causing frustration among shareholders. Despite setbacks, the company remains committed to selling all assets and has taken steps to ensure financial sustainability during the process. The CEO expects agreements for the sale of assets by the end of 2024, potentially doubling the current share price within the next 3-6 months. seekingalpha.com - 2 months ago
IRIDEX Corporation (IRIX) Q2 2024 Earnings Call Transcript IRIDEX Corporation (NASDAQ:IRIX ) Q2 2024 Earnings Conference Call August 8, 2024 5:00 PM ET Company Participants Philip Taylor – Investor Relations David Bruce – Chief Executive Officer Fuad Ahmad – Interim Chief Financial Officer Conference Call Participants Tom Stephan – Stifel Operator Good day, and thank you for standing by. At this time I would like to welcome everyone to IRIDEX Second Quarter 2024 Earnings Conference Call. seekingalpha.com - 3 months ago
Iridex (IRIX) Reports Q2 Loss, Misses Revenue Estimates Iridex (IRIX) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.17 per share a year ago. zacks.com - 3 months ago
IRIDEX Corporation (IRIX) Q1 2024 Earnings Call Transcript IRIDEX Corporation (NASDAQ:IRIX ) Q1 2024 Earnings Conference Call May 14, 2024 5:00 PM ET Company Participants Trip Taylor - Investor Relations David Bruce - Chief Executive Officer Fuad Ahmad - Interim Chief Financial Officer Conference Call Participants Tom Stephan - Stifel Operator Good day, and thank you for standing by. Welcome to Q1 2024 IRIDEX Earnings Conference Call. seekingalpha.com - 6 months ago
Iridex (IRIX) Reports Q1 Loss, Misses Revenue Estimates Iridex (IRIX) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.13 per share a year ago. zacks.com - 6 months ago
Iridex Reports First Quarter 2024 Financial Results MOUNTAIN VIEW, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the first quarter ended March 30, 2024, and provided a business update. globenewswire.com - 6 months ago
Iridex's Strategic Review Process Should Bear Fruit 'Soon' Iridex Corporation is undergoing a strategic review process to unlock shareholder value. The company is likely to sell its retina business line and potentially parse it out in more than one transaction "soon." The glaucoma business line is highly promising but likely needs to be in the hands of a bigger company to reach its full potential. seekingalpha.com - 7 months ago
IRIDEX Corporation (IRIX) Q4 2023 Earnings Call Transcript IRIDEX Corporation (IRIX) Q4 2023 Earnings Call Transcript seekingalpha.com - 7 months ago
Iridex (IRIX) Reports Q4 Loss, Lags Revenue Estimates Iridex (IRIX) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.07 per share a year ago. zacks.com - 7 months ago
Iridex Reports Fourth Quarter and Full Year 2023 Financial Results MOUNTAIN VIEW, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the fourth quarter and full year ended December 30, 2023, and provided a business update. globenewswire.com - 7 months ago
8. Profile Summary

IRIDEX Corporation IRIX

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 28.1 M
Dividend Yield 0.00%
Description IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.
Contact 1212 Terra Bella Avenue, Mountain View, CA, 94043 https://www.iridex.com
IPO Date Feb. 16, 1996
Employees 111
Officers Mr. Patrick Mercer Chief Executive Officer & President Mr. Scott A. Shuda J.D. Executive Chairman Mr. Fuad Ahmad Interim Chief Financial Officer Ms. Leigh Salvo Head of Investor Relations